US FDA approves Leqselvi (deuruxolitinib), an oral JAK inhibitor for the treatment of severe alopecia areata

Sun Pharma

25 July 2024 - Leqselvi delivered statistically significant efficacy across two Phase 3 clinical trials.

Sun Pharmaceutical today announced that the US FDA approved Leqselvi (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata.

Read Sun Pharma press release 

Michael Wonder

Posted by:

Michael Wonder